首页 工具
登录
全部产品 抑制剂&激动剂 化合物库 天然产物 技术服务 重组蛋白 会员中心 联系我们
购物车
抑制剂&激动剂 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架 DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道 代谢 微生物学 神经科学
化合物库 活性化合物库 •   通用已知活性库 •   上市状态分类 •   疾病类型分类 •   通路靶点分类 天然产物库 •   高通量筛选天然产物库 •   特色天然产物库 •   天然产物衍生物库 Fragment片段库 •   通用片段库 •   特色片段库 类药性化合物库 •   多样性核心库Part2 •   多样性核心库Part1 化合物库深度定制
技术服务 计算机辅助药物设计 •   虚拟筛选 实体化合物活性筛选 •   分子结合&互作检测 药物设计和结构优化 天然产物 试剂盒 Cell Counting Kit-8 (CCK-8) Inhibitor Cocktails SYBR Green qPCR Master Mix (No ROX) 染料试剂 多肽产品 抗体抑制剂 PROTAC
重组蛋白 细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体 •   受体酪氨酸激酶 CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白 CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白
信号通路 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架
DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道
代谢 微生物学 神经科学 NF-κB信号通路 氧化还原 PI3K/Akt/mTOR信号通路 蛋白酶体
干细胞 蛋白酪氨酸激酶 泛素化 PROTAC 其他
活性化合物库 上市药物库 临床期小分子药物库 已知活性化合物库 FDA上市及药典收录分子库 抗癌药物库 抗病毒库 铁死亡化合物库
天然产物库 高通量筛选天然产物库 Ro5类药天然产物库 中药单体化合物库 糖类及苷类化合物库 稀有天然产物库 天然产物衍生物库 天然产物单体化合物库
Fragment片段库 高溶解性片段库 精选片段库 高溶解性多官能团片段化合物库 高溶解性卤化片段化合物库 药物片段库 Mini片段亲电杂环化合物库 高溶解性微型片段化合物库
类药性化合物库 多样性核心库Part2 多样性核心库Part1 药物靶点库 多样性核心预制库 Golden骨架库 Mini骨架库 化合物库深度定制
TargetMol Compound Library
天然产物库 高通量筛选天然产物库 特色天然产物库 天然产物衍生物库 虚拟筛选天然产物库
结构类型 萜类 类固醇 类黄酮 醌类 香豆素 木脂素 多糖和糖苷
苯丙烷 生物碱 酚类 其他
植物来源 列当科 水龙骨科 南洋杉科 报春花科 海金沙科 商陆科 买麻藤科
萝藦科 肉豆蔻科 鸭跖草科 交让木科 三白草科 海桐花科 五味子科 红厚壳科
莲叶桐科 胡桃科 石杉科 桔梗科 百合科 忍冬科 漆树科
计算机辅助药物设计 虚拟筛选 分子对接 反向找靶 分子动力学模拟
基于靶点筛选实体化合物活性筛选 分子结合&互作检测 酶学靶点活性检测 核受体靶点活性检测 GPCR靶点活性检测
基于表型筛选实体化合物活性筛选 细胞增殖检测 细胞周期检测 细胞凋亡检测 药代动力学研究
药物设计和结构优化 化合物定制合成 分子砌块 网络药理学平台 软件平台
细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体
CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白
CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白 酶 •   氧化还原酶 •   转移酶
病毒蛋白 •   冠状病毒蛋白 •   流感病毒蛋白 荧光蛋白 其他蛋白

搜索结果

Search Results for " hla-a*11:01 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Species：
Human (154)
Human & Mouse (4)
Expression System：
HEK293 Cells (143)
E. coli (15)
Tag：
C-His-Avi (152)
C-His (1)
C-hFc (1)
C-hFc-Avi (1)
C-mFc (1)
N-His-Avi (1)
Tag Free (1)
Cat. No. Product Name Species Expression System
TMPK-01426 Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)

HLA-A*02:01,Peptide Re

Human HEK293 Cells
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
TMPK-01503 HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi)

Macropain chain 7,LMP-2,RING12,LM...

 Human HEK293 Cells
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma...
TMPK-01488 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

K-RAS4A,MHC,GTPase Kras,...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01498 HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Tetramer Protein, Human, MHC (His & Avi)

Proteasome chain 7,MHC,RING12,RMF,LMP2,LMP...

 Human HEK293 Cells
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma...
TMPK-01425 Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated

MHC,HLA-A*02:01,Peptide ...

 Human HEK293 Cells
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
TMPK-01489 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

K-RAS2A,NS3,KRAS1,KRAS2,...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01502 HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

PSMB9,LMP2,Macropain chain 7,MHC,...

 Human HEK293 Cells
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma...
TMPK-01399 HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-RAS2A,NS3,KRAS2,CFC2,K-RA

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01479 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

NS3,KRAS1,K-Ras 2,K-RAS2A

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01458 HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

K-Ras 2,GTPase Kras,KRAS...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432 HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

RASK2,K-RAS4A,K-RAS4B,KR...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01529 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

K-RAS4A,KRAS1,MHC,K-RAS2...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

C-K-RAS,KI-RAS,KRAS1,K-RA

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

MHC,NS,KRAS1,K-RAS2A,GTPa

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01433 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

GTPase Kras,NS3,K-Ras 2,K-RA<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01428 HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

CFC2,K-RAS4B,K-Ras 2,C-K-RAS,R

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01461 HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

C-K-RAS,KRAS,RASK2,K-Ras...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

RASK2,CFC2,GTPase Kras,KRA

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01490 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

K-RAS2A,GTPase Kras,K-R<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01431 HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)

RALD,C-K-RAS,MHC,K-RAS2A...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01528 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTP<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01465 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS2A,CFC2,KRAS,GTPa

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01507 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

K-RAS2A,K-RAS4B,KI-RAS,R...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01401 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

MHC,CFC2,K-Ras 2,RALD,K-RAS4A...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01457 HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-Ras 2,CFC2,RALD,MHC,KRAS,K-R

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01471 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

CFC2,KRAS,K-RAS4B,MHC,K-RAS2B,KR<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01438 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

RASK2,KRAS2,KRAS1,MHC,C-K-RA<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01462 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-RAS4A,K-RAS2A,CFC2,KR<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01460 HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

MHC,K-RAS2A,KI-RAS,K-RAS...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01427 HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

C-K-RAS,K-RAS4B,GTPase Kra

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01525 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01536 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GT...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

C-K-RAS,K-RAS4A,GTPase K...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01537 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-RAS4A,NS,C-K-RAS,RALD,...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01400 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

NS,KRAS1,RALD,K-RAS2A,K-...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01405 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

KI-RAS,RASK2,K-Ras 2,MHC,KRA<...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

KRAS1,C-K-RAS,K-RAS4B,RA...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

K-Ras 2,KI-RAS,CFC2,KRAS1,GTP...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01439 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

KRAS,GTPase Kras,K-RAS2<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

K-RAS2A,RALD,NS3,K-Ras 2...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

RASK2,KI-RAS,C-K-RAS,KRA...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01429 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

MHC,K-Ras 2,NS,K-RAS4A,KRA

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01404 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

NS,KRAS,KRAS1,KRAS2,MHC,RA

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01402 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

KRAS1,NS,CFC2,K-RAS4B,RASK2,K-R

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPY-02005 Mucin-1/MUC1 Protein, Human, Recombinant (hFc)

PEM,ADMCKD1,CA15-3,CD227,MCD,mucin 1, cell...

 Human HEK293 Cells
Mucin-1/MUC1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 42 kDa and the accession number is P15941-11.
TMPY-04340 Mucin-1/MUC1 Protein, Human, Recombinant

mucin 1, cell surface associated,...

 Human HEK293 Cells
Mucin-1/MUC1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 15.4 kDa and the accession number is P15941-11.
TMPK-01494 HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)

HLA-A,HLA-A...

 Human HEK293 Cells
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy.
TMPK-01493 HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi)

MZ2-D,Melanoma-associate...

 Human HEK293 Cells
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
TMPK-01495 HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein, Human, MHC (His & Avi)

Melanoma-associated ...

 Human HEK293 Cells
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
TMPK-01485 HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein, Human, MHC (His & Avi)

CDHF6,DG3,DSG3,PVA,DSG-3,Desmoglein-3

 Human HEK293 Cells
DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
------------------------ 更多 ------------------------

重组蛋白

Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01426
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01503
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01488
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01498
Species: Human
Expression System: HEK293 Cells
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01425
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01489
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01502
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01399
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01479
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01458
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01432
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01529
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01463
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01518
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01433
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01428
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01461
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01434
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01490
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01431
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01528
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01465
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01507
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01401
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01457
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
Cat.No: TMPK-01471
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01438
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01462
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01460
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01427
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01525
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01536
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01464
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01537
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01400
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01405
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
Cat.No: TMPK-01443
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01403
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01439
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01430
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01440
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01429
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01404
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01402
Species: Human
Expression System: E. coli
Mucin-1/MUC1 Protein, Human, Recombinant (hFc)
Cat.No: TMPY-02005
Species: Human
Expression System: HEK293 Cells
Mucin-1/MUC1 Protein, Human, Recombinant
Cat.No: TMPY-04340
Species: Human
Expression System: HEK293 Cells
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01494
Species: Human
Expression System: HEK293 Cells
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01493
Species: Human
Expression System: HEK293 Cells
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01495
Species: Human
Expression System: HEK293 Cells
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01485
Species: Human
Expression System: HEK293 Cells
--------- 更多 ---------
TargetMol®
关于我们 隐私声明 前沿资讯 相关条款
相关支持
联系我们 全球经销商 订购指南 技术支持
技术资源
产品目录 产品引用文献 信号通路 溶液计算器
订阅 TargetMol®
订阅以获得我们的产品更新和特惠活动!
获取我们的最新产品和特惠活动!
TargetMol®
相关支持
技术资源
我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。
Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4 沪公网安备 31010602006700号 沪公网安备 31010602006700号
联系我们
400-820-0310
service@tsbiochem.com
2881945090（终端用户）
2885109491（经销商） 

上海市静安区江场三路238号8楼